Here, we report a case of multidrug resistance in a patient with chronic hepatitis B. The patient sequentially received lamivudine, adefovir dipivoxil and entecavir, and subsequently developed single-, double-and triple-drug-resistant HBV strains. We consider this case report important because it documents, for the first time, that triple-drug-resistant HBV strains identified in a clinical setting were suppressible by lamivudine add-on adefovir dipivoxil when tenofovir disoproxil fumarate was not available.
Chronic HBV infection affects 350 and 93 million people worldwide and in China, respectively. Treatment of chronic HBV infection is aimed at suppressing viral replication to the lowest possible level to prevent disease progression [1, 2] . Four nucleoside/nucleotide analogues (NAs) are currently approved in China for the treatment of HBV infection: lamivudine (3TC), adefovir dipivoxil (ADV), entecavir (ETV) and telbivudine (LdT). Viral resistance is the main drawback of long-term antiviral therapy. The resistant mutations are located in the reverse transcriptase (RT) region of the HBV polymerase gene. Primary mutations that confer resistance to 3TC, ADV, LdT and ETV are classically identified as rtM204I/ rtM204V, rtN236T/rtA181V(T), rtM204I and rtT184/ rtS202/rtM250 substitutions in conjunction with 3TC-resistant mutations, respectively [3] [4] [5] . The primary mutations are often concomitant with compensatory mutations, such as rtL80I/V, rtV173L and rtL180M. Previous treatment with suboptimal regimens and infection with drug-resistant viral strains increases the occurrence of resistance and might favour the development of multidrug-resistant (MDR) HBV [6, 7] . MDR HBV has mutations collocated on the same viral genome that confer resistance to multiple antiviral agents that have a favourable cross-resistance profile, that is, resistance to NAs. Although MDR HBV development has caused great concern to date, clinical reports on MDR HBV infection are limited and restricted to ADV and 3TC double resistance [8] [9] [10] [11] [12] [13] .
A 38-year-old Chinese man who had genotype C chronic hepatitis B (CHB) with a hepatitis B e antigen (HBeAg)-positive status was started on 3TC (100 mg/ day) plus interferon (IFN)-α2b (3×10 6 IU/day administered intramuscularly) combination therapy in June 2002. The standard procedure used for CHB diagnosis was based on the Chinese Management Scheme of Diagnostic and Therapy Criteria of Viral Hepatitis and has been described elsewhere [14] . After 10 months of treatment with 3TC (100 mg/day) and IFNα2b (3×10 6 IU/day administered intramuscularly), the patient's serum HBV DNA decreased from 9.74×10 7 IU/ml (5 copies =1 IU) at baseline to 2.18×10 3 IU/ml, and alanine transaminase (ALT) levels decreased from 394 U/l to 42 U/l. After month 10, IFN-α2b was suspended because of progressive decrease of the patient's platelet count (<48×10 9 cells/l) and 3TC monotherapy 5 IU/ml) and biochemical breakthrough (ALT increase to 121 U/l) developed after 10 months of ETV treatment. In April 2007, the therapy was switched to ADV (10 mg/day) for 18 months; on the basis that the patient's platelet count had restored to a normal level, IFN-α2b (3.6×10 6 IU/2 days administered subcutaneously) was given again for the first 6 months and suspended because of thyroid functional impairment. This adaptation decreased HBV DNA to 3.34×10 4 IU/ml and normalized ALT levels. In October 2008, 3TC (100 mg/ day) was added in addition to ADV and therapy was continued for 13 months. HBV DNA further decreased to <100 IU/ml and ALT levels remained normal. HBeAg loss continued and anti-HBe status fluctuated between negative and low positive for 2.5 years. The timing of antiviral agent administration, together with serum HBV DNA and ALT levels are shown in Figure 1A .
Serum samples were collected at 22 time points. HBV gene fragments (nucleotides 54-1278) encompassing the complete RT gene was amplified by an inhouse nested PCR assay [15] . The assay had a lower detection limit of 20 IU/ml, which was more sensitive than the real-time quantitative PCR assays for HBV DNA quantification currently in clinical use (100 IU/ ml; Fosun Pharmaceutical Co., Ltd., Shanghai, China). S5 S6S7 S8 S9 S10 S11-S14 S15 S16 S17 S18 S19 S20 S21 S22
HBV DNA <100 IU/ml The PCR products were directly sequenced and also cloned into a pGEM-Teasy Vector System II (Promega, Madison, WI, USA) for clonal sequencing (20-40 clones for each sample). Mutations at the sites of rt80, rt84, rt173, rt180, rt181, rt184, rt202, rt204, rt236 and rt250 were monitored. The resistant activities of the monitored mutations in single or combination have been previously demonstrated to be associated with antiviral resistance. In addition, direct PCR sequencing of HBV basal core promoter/precore region was carried out as described [15] . The patient had good compliance with the prescribed drug regimen and had no obvious side effects to NA therapy. Histological information was not available because the patient was unwilling to undergo liver biopsy. Figure 1B summarizes the proportion of the wildtype and resistant HBV isolates in cloned sequence analysis in chronological order. A 3TC-resistant mutant with rtM204I emerged in 22 months and became dominant after 33 months of 3TC treatment, and caused virological and biochemical breakthroughs. After switching to ADV, 3TC-resistant mutants were suppressed and ADVresistant mutants with rtA181T and rtA181V emerged. After ETV administration, 3TC-resistant HBV strains initially proliferated after 1 month and ETV-resistant HBV strains subsequently proliferated after 6 months, which caused virological breakthrough and then biochemical breakthrough, respectively. After ADV treatment was resumed, the ETV-resistant mutant remained dominant for 7 months before an MDR strain with rtL180M+rtA181V+rtS202G+rtM204V emerged. After an additional 11 months, ADV-resistant mutants with rtN236T with or without rtA181T were selected as the dominant HBV strains, together with minor populations of ETV-resistant, 3TC-resistant and wild-type strains. 3TC add-on ADV significantly inhibited HBV replication in 5 months. Interestingly, MDR HBV strains with rtL180M+ rtA181V+rtS202G+rtM204V+rtN236T were selected in quantity and they were concomitant with the ETV-resistant strain (rtL180M+rtS202G+rtM204V), the ADV-resistant strain (rtN236T) and another MDR strain (rtL180M+rtS202G+rtM204V+ rtN236T). Furthermore, 8 months later, MDR strains disappeared and left a complex mixture of strains (in the 33 cloned HBV strains) with signature mutations comprising rtV84M+rtM250I (14/33), rtM250I (2/33), rtA181V (5/33), rtA181T (4/33), rtL180M+ rtM204V (2/33), rtV173L+rtL180M+rtM204V (2/33), rtL180M+rtS202G+rtM204V (2/33), and rtV84M+rt V173L+rtL180M+rtS202G+rtM204V (1/33). An additional 5 months of 3TC plus ADV treatment maintained HBV DNA<100 IU/ml; however, altered mutational patterns were detected in cloned strains with genotypic resistance to ETV (27/29) or 3TC (2/29). Direct sequencing generally had consistent results with cloning sequencing, but could not detect the minor populations of resistant mutants that can be detected by clonal analysis, and could not distinguish whether complex mutations were from same HBV genome or different HBV genomes (Table 1) .
Clinical emergence of MDR HBV is infrequent because combinations of NAs are usually chosen so that their antiviral activities are complementary. MDR HBV replicates its genome less efficiently than either the wild-type HBV or mutants that are resistant to single drugs [8] . A spectrum of HBV genetic variants is generated continuously by low-fidelity replication. Mutation(s) conferring a selective advantage to a variant will give rise to virions and become the dominant species under the pressure of antiviral drugs [16] . The discovery of a case with the three novel MDR HBV strains (GenBank accession numbers GQ402158, GQ402161 and GQ402162) was on the basis of population-based screening of HBV RT genes in CHB patients [17] , and largely contributed to the highly sensitive nested PCR assay, which allowed us to analyse samples with quite low viral load as in our previous severe acute respiratory syndrome-coronavirus quasispecies study [18] . Phylogenetic analyses of representative cloned sequences supported that Sample  RT  BCP/PC   S1  WT  A1762T, G1764A  S2  WT  A1762T, G1764A  S3  WT  A1762T, G1764A  S4  WT  A1762T, G1764A  S5  WT  A1762T, G1764A  S6  M204I  A1762T, G1764A  S7  M204I/V  A1762T, G1764A  S8  L80V  A1762T, G1764A  S9  WT  A1762T, G1764A  S10  WT  A1762T, G1764A  S11  WT  A1762T, G1764A  S12  L180M, A181V, M204V  Undetectable  S13  L180M  Undetectable  S14  M204I/V  A1762T, G1764A, G1896A  S15  L180M, S202G, M204V  A1762T, G1764A, G1896A  S16  L180M, S202G, M204V  A1762T, G1764A, G1896A  S17  L180M, S202G, M204V  A1762T, G1764A, G1896A  S18  L180M, S202G, M204V  A1762T, G1764A, G1896A  S19  N236T  A1762T, G1764A, G1896A  S20  L180M, S202G, M204V,  Undetectable  N236T  S21  V84M, L180M, A181T/V,  Undetectable  S202G, M204V, M250I  S22 L180M, S202G, M204V Undetectable the development of MDR HBV strains was a stepwise process ( Figure 2 ). We also found that MDR HBV strains were suppressible by ADV plus 3TC treatment; however, the mechanism needs clarification. It has been suggested that combination therapy of 3TC and ADV is less effective at suppressing HBV strains when mutations that confer resistance to 3TC and ADV are present on the same viral genome compared with when the mutations are present on different genomes in a mixed population [8, 19] . As viral fitness and the potency of the antiviral agent are key factors that influence the development of resistance [20] , it could be speculated that the transient replication advantage of the MDR strains in the initial interaction with 3TC was taken over by other HBV strains that have a greater replication competency under increasing pressure of 3TC and ADV. The immune response against these MDR strains might also have contributed to the clearance of these strains, especially if they had fitness impairment. Our findings could have important clinical implications because tenofovir disoproxil fumarate, which is strongly recommended for treating complex resistance [1, 2] , has not been approved for use in many countries, including China. In addition, there were some interesting phenomena observed in the study. Firstly, ETV was able to rapidly 'recall' preexisting 3TC-resistant mutants, which could be the prelude of ETV-resistant HBV emergence ( Figure 1B ; S12-S14). Secondly, coexistence of individual drugresistant HBV strains was likely a driving factor of MDR HBV evolution ( Figure 1B ; S19-S20). Lastly, 3TC administration was able to 'recall' pre-existing ETV-resistant mutants ( Figure 1B ; S20). Taken together, we have made two important findings: firstly, novel HBV strains resistant to 3TC, ADV and ETV can emerge clinically and are associated with sequential use of individual drugs; secondly, the MDR HBV strains can be suppressed by combination of 3TC and ADV. S22 L180M+T184L+M204V S22 L180M+T184L+M204V+N236S S22 L80P+L180M+S202G+M204V S22 L180M+S202G+M204V+M250I S20 L180M+A181V+S202G+M204V+N236T GQ40216 S20 L180M+S202G+M204V+N236T GQ402162 S21 V84M+M250I GU324995 S12 A181V GQ402155 S17 L180M+A181V+S202G+M204V GQ402158 S19 N236T GQ402159 S14 L180M+S202G+M204 GQ402156 S15 L180M+M204V+T184A GQ402157 S6 L80V+M204I GQ402152 S7 L180M+M204V GQ402153 S10 A181T GQ402154 S19 A181T+N236T GQ402160 S1 WT GQ402151 
